- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07647783
A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets
9. juni 2026 oppdatert av: InnovStone Therapeutics Limited
A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2072 Tablets in Healthy Participants
This is a first-in-human study to evaluate the safety, tolerability, PK, and PD characteristics of SYH2072 Tablets after single and multiple oral doses in healthy participants.
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
112
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Clinical Trials Information Group officer
- Telefonnummer: +86-0311-69085587
- E-post: ctr-contact@cspc.cn
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100029
- Rekruttering
- Beijing AnZhen Hospital, Capital Medical University
-
Ta kontakt med:
- Yang Lin
- Telefonnummer: +86-18910778667
- E-post: linyang@anzhengcp.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Participants must be fully informed about the study content, procedures, and potential adverse reactions, and voluntarily sign the written informed consent form (ICF) before the study;
- Sex: Male or female;
- Age: 18-55 years old (inclusive);
- Body mass index in the range of 19 to 30 kg•m-2 [Body Mass Index (BMI) = weight/height2 (kg•m^2)] (inclusive), with a body weight of no less than 50 kg for males (inclusive) and no less than 45 kg for females (inclusive);
- Participants are able to communicate well with the investigator and are able to complete the study in accordance with the protocol.
Exclusion Criteria:
- History of severe allergic diseases or allergic constitution (allergy to ≥ 3 drugs or foods);
- Use of corticosteroid drugs within 3 months prior to screening;
- Past and/or current clinically significant medical conditions, including but not limited to diseases of the circulatory, hematologic or hematopoietic, respiratory, endocrine, urinary, digestive, nervous or psychiatric systems, infections, tumors, severe trauma, or any other disease that the investigator considers should be excluded or may interfere with the interpretation of the study results;
- Postural tachycardia (heart rate increase > 30 beats/minute upon standing) or postural hypotension (decrease in SBP ≥ 20mmHg or DBP ≥ 10mmHg upon standing) at screening;
- Have undergone major surgery within 6 months prior to screening, or plan to undergo major surgery during the study;
- Potassium ion level outside the normal range in clinical chemistry tests at screening, or serum creatinine > upper limit of normal (ULN);
- Any one of the following at screening: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) > 1.2×ULN (one re-test within 1 week is allowed);
- Estimated glomerular filtration rate (eGFR) < 90mL/min/1.73 m2 at screening;
- Prolonged QT/QTc interval at screening (QTcF ≥ 450ms for males, ≥ 470ms for females);
- Positive for any of the following: HBsAg, HCV antibody, syphilis antibody, or HIV antibody;
- Blood loss or blood donation exceeding 200mL within 3 months prior to screening (excluding menstruation for females), and/or platelet donation within 2 weeks;
- Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or dietary supplements (including vitamins, health products, etc.) within 28 days prior to screening;
- History of drug abuse, and/or use of illicit drugs within 3 months prior to screening, and/or habitual use of any psychotropic drugs, including Chinese herbal medicines, and/or a positive urine drug screen;
- Average daily smoking of more than 5 cigarettes (or an equivalent amount of tobacco in e-cigarettes) within 3 months prior to screening, and/or unwilling to avoid using any tobacco products during the study;
- Regular alcohol consumption within 6 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360mL of 5% alcohol beer or 45mL of 40% alcohol spirits or 150mL of 12% alcohol wine), and/or inability to abstain from alcohol intake during the study, and/or a positive breath alcohol test;
- Excessive daily consumption of tea, coffee, and/or caffeinated beverages (8 cups or more, 1 cup = 250mL) within 1 month prior to screening, and/or unwilling to abstain from tea, coffee, and/or caffeinated foods, grapefruit and/or grapefruit juice, and/or poppy-containing products during the study;
- Having a fertility plan (including sperm or egg donation) from the time of signing the ICF until 3 months after the last dose, and/or unwilling to use an effective non-drug method of contraception;
- Participation in any clinical study within 3 months prior to screening;
Participants who may be unable to complete the study for other reasons or who are deemed unsuitable for inclusion by the investigator.
In addition to the above requirements, female participants who meet the following criteria will also be excluded:
- Pregnant or lactating women;
- Use of oral contraceptives within 28 days prior to screening;
- Use of long-acting estrogen and/or progestogen injections and/or implants within 6 months prior to screening; 23)Women of childbearing potential who have had unprotected sexual intercourse with a partner within 28 days prior to dosing.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Single Ascending Doses (SAD, Part A)
In this part, 6 ascending dose cohorts (10 participants per cohort) will be studied.
Within each cohort, participants will be randomized in a 4:1 ratio to receive either SYH2072 or placebo.
|
SYH2072 tablets will be administered as a single or multiple oral doses.
SYH2072 placebo tablets will be administered as a single or multiple oral doses.
|
|
Eksperimentell: Food Effect (FE, Part B)
12 participants and single dose food effect cohort.
|
SYH2072 tablets will be administered as a single or multiple oral doses.
|
|
Eksperimentell: Experimental: Multiple Ascending Doses (MAD, Part C)
In this part, 4 ascending dose cohorts (10 participants per cohort) will be studied.
Within each cohort, participants will be randomized in a 4:1 ratio to receive either SYH2072 or placebo.
|
SYH2072 tablets will be administered as a single or multiple oral doses.
SYH2072 placebo tablets will be administered as a single or multiple oral doses.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The rate of Adverse events
Tidsramme: Through study completion, an average of 8 months
|
The rate of Adverse events occur during the whole study
|
Through study completion, an average of 8 months
|
|
The rate of normality or abnormality of electrocardiogram
Tidsramme: Through study completion, an average of 8 months
|
The rate of normality or abnormality of electrocardiogram during the whole study
|
Through study completion, an average of 8 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
15. januar 2026
Primær fullføring (Antatt)
1. februar 2027
Studiet fullført (Antatt)
1. april 2027
Datoer for studieregistrering
Først innsendt
8. mai 2026
Først innsendt som oppfylte QC-kriteriene
9. juni 2026
Først lagt ut (Faktiske)
15. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
15. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
9. juni 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- SYH2072-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .